MY200172A - Methods and compositions for treating sleep apnea - Google Patents

Methods and compositions for treating sleep apnea

Info

Publication number
MY200172A
MY200172A MYPI2019006319A MYPI2019006319A MY200172A MY 200172 A MY200172 A MY 200172A MY PI2019006319 A MYPI2019006319 A MY PI2019006319A MY PI2019006319 A MYPI2019006319 A MY PI2019006319A MY 200172 A MY200172 A MY 200172A
Authority
MY
Malaysia
Prior art keywords
compositions
methods
sleep apnea
treating sleep
nri
Prior art date
Application number
MYPI2019006319A
Other languages
English (en)
Inventor
D Andrew Wellman
Luigi Taranto-Montemurro
Original Assignee
Brigham & Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63918622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY200172(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brigham & Womens Hospital Inc filed Critical Brigham & Womens Hospital Inc
Publication of MY200172A publication Critical patent/MY200172A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MYPI2019006319A 2017-04-28 2018-04-26 Methods and compositions for treating sleep apnea MY200172A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762491504P 2017-04-28 2017-04-28
US201762558814P 2017-09-14 2017-09-14
PCT/US2018/029518 WO2018200775A1 (en) 2017-04-28 2018-04-26 Methods and compositions for treating sleep apnea

Publications (1)

Publication Number Publication Date
MY200172A true MY200172A (en) 2023-12-12

Family

ID=63918622

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019006319A MY200172A (en) 2017-04-28 2018-04-26 Methods and compositions for treating sleep apnea

Country Status (22)

Country Link
US (4) US11123313B2 (enExample)
EP (1) EP3615016A4 (enExample)
JP (3) JP7373997B2 (enExample)
KR (3) KR102682159B1 (enExample)
CN (2) CN119185558A (enExample)
AU (3) AU2018260666B2 (enExample)
BR (1) BR112019022483A2 (enExample)
CA (1) CA3061468A1 (enExample)
CO (1) CO2019013180A2 (enExample)
CR (1) CR20190546A (enExample)
DO (1) DOP2019000274A (enExample)
EC (1) ECSP19084058A (enExample)
GE (4) GEAP202416602A (enExample)
MA (1) MA49069A (enExample)
MX (2) MX394941B (enExample)
MY (1) MY200172A (enExample)
NI (1) NI201900110A (enExample)
PH (1) PH12019502427A1 (enExample)
SG (2) SG11201909973UA (enExample)
UA (1) UA127759C2 (enExample)
WO (1) WO2018200775A1 (enExample)
ZA (1) ZA201907158B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102682159B1 (ko) * 2017-04-28 2024-07-08 더 브리검 앤드 우먼즈 하스피털, 인크. 수면 무호흡을 치료하기 위한 방법 및 조성물
CA3089712A1 (en) * 2018-01-30 2019-08-08 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
CN108309261B (zh) * 2018-02-11 2020-05-22 西安交通大学 一种猝死预警方法及装置和系统
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
MX2021004883A (es) * 2018-10-31 2021-08-05 Apnimed Inc Delaware Metodos y composiciones para tratar apnea del sue?o.
KR20210125507A (ko) 2019-02-08 2021-10-18 더 브리검 앤드 우먼즈 하스피털, 인크. 수면성 무호흡의 치료 방법 및 조성물
WO2021091902A1 (en) * 2019-11-04 2021-05-14 Apnimed, Inc. (Delaware) Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea
MX2022013823A (es) 2020-05-05 2023-01-11 Apnimed Inc Delaware Formas polimorficas de clorhidrato de (r)-oxibutinina.
CN114159568B (zh) * 2020-09-11 2025-08-01 北京原基华毅生物科技有限公司 Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
RU2757470C1 (ru) * 2020-11-19 2021-10-18 Ренат Рашитович Ахмеров Способ лечения храпа с помощью введения тромбоцитарной аутологичной плазмы
US20240075035A1 (en) * 2021-01-14 2024-03-07 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
JP2024508498A (ja) * 2021-03-04 2024-02-27 アプニメッド,インコーポレイテッド(デラウェア) 睡眠時無呼吸の治療における使用のためのレボキセチン及びムスカリン受容体拮抗薬(mra)の組み合わせ
CA3213576A1 (en) * 2021-04-16 2022-10-20 Lawrence G. Miller Combination of a norepinephrine reuptake inhibitor and a cannabinoid for use in treating sleep apnea
WO2022266440A1 (en) * 2021-06-17 2022-12-22 Apnimed, Inc. (Delaware) Norepinephrine reuptake inhibitors for treating sleep apnea
JP2024534173A (ja) * 2021-08-31 2024-09-18 アプニメッド,インコーポレイテッド(デラウェア) 睡眠時無呼吸を治療するための方法及び組成物
JP2024545289A (ja) * 2021-12-22 2024-12-05 バイエル・アクチエンゲゼルシヤフト 睡眠時無呼吸の治療のためのtask1/3チャネル遮断薬とノルエピネフリン再取込み阻害薬との組合せ
AU2022418121A1 (en) 2021-12-22 2024-07-04 Bayer Aktiengesellschaft Combination of an α2-adrenoceptor subtype c (alpha-2c) antagonist with a norepinephrine reuptake inhibitor for the treatment of sleep apnea
CN118434414A (zh) 2021-12-22 2024-08-02 拜耳公司 用于治疗睡眠呼吸暂停的α2-肾上腺素受体亚型C(α-2C)拮抗剂与毒蕈碱受体拮抗剂的结合物
EP4522149A1 (en) * 2022-05-13 2025-03-19 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2371923A1 (en) 1999-05-20 2000-11-30 Thomas P. Jerussi Methods for treatment of asthma using s-oxybutynin
WO2001062236A2 (en) * 2000-02-24 2001-08-30 Pharmacia & Upjohn Company New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
WO2006023702A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders with setiptiline
AU2005319367B2 (en) 2004-12-20 2012-05-24 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
WO2012103398A2 (en) * 2011-01-28 2012-08-02 Jian-Qiang Fan Methods for treating obstructive sleep apnea
KR102682159B1 (ko) * 2017-04-28 2024-07-08 더 브리검 앤드 우먼즈 하스피털, 인크. 수면 무호흡을 치료하기 위한 방법 및 조성물
CA3089712A1 (en) * 2018-01-30 2019-08-08 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea

Also Published As

Publication number Publication date
US11123313B2 (en) 2021-09-21
KR102682159B1 (ko) 2024-07-08
AU2018260666B2 (en) 2022-07-21
MA49069A (fr) 2020-03-04
SG11201909973UA (en) 2019-11-28
US20240189261A1 (en) 2024-06-13
JP2025169279A (ja) 2025-11-12
CO2019013180A2 (es) 2020-02-07
AU2022241471A1 (en) 2022-10-27
WO2018200775A1 (en) 2018-11-01
NZ758564A (en) 2023-12-22
AU2025230729A1 (en) 2025-10-02
CN110799181A (zh) 2020-02-14
JP2020517719A (ja) 2020-06-18
PH12019502427A1 (en) 2020-10-05
MX2022010349A (es) 2022-09-19
MX394941B (es) 2025-03-24
US20200054583A1 (en) 2020-02-20
US20240261239A1 (en) 2024-08-08
EP3615016A1 (en) 2020-03-04
BR112019022483A2 (pt) 2020-05-12
UA127759C2 (uk) 2023-12-27
DOP2019000274A (es) 2019-12-30
ZA201907158B (en) 2021-09-29
AU2018260666A1 (en) 2019-11-14
NI201900110A (es) 2020-03-18
GEP20247617B (en) 2024-04-25
GEAP202416602A (en) 2024-10-10
CR20190546A (es) 2020-04-08
JP7373997B2 (ja) 2023-11-06
SG10202111623TA (en) 2021-12-30
US20210401777A1 (en) 2021-12-30
GEP20257788B (en) 2025-08-25
MX2019012729A (es) 2019-12-19
ECSP19084058A (es) 2020-01-31
JP2023139000A (ja) 2023-10-03
GEP20227387B (en) 2022-06-10
KR20190140019A (ko) 2019-12-18
CA3061468A1 (en) 2018-11-01
KR20250145704A (ko) 2025-10-13
KR20240042261A (ko) 2024-04-01
EP3615016A4 (en) 2021-02-24
CN119185558A (zh) 2024-12-27

Similar Documents

Publication Publication Date Title
PH12019502427A1 (en) Methods and compositions for treating sleep apnea
MX2025004365A (es) Metodos y composiciones para el tratamiento de la apnea del sue?o
MX2024001713A (es) Metodos y composiciones para tratar la apnea del sue?o.
CR10342A (es) INHIBIDORES DE LOS CANALES DE IONES TASK-1 y TASK-3
GEP20227366B (en) Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
PH12018501235A1 (en) 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders
WO2014120936A3 (en) Treatments for depression and other diseases with a low dose agent
JOP20190141A1 (ar) أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي
PH12019501458A1 (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
MX2024013184A (es) Metodos y composiciones para tratar apnea del sue?o
MX2021003428A (es) Antagonistas del receptor adrenérgico a2 subtipo c (alfa-2c) para el tratamiento de la apnea del sueño.
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
MY167553A (en) Layered soft palate support and implantation method
MX2021006081A (es) Proceso para la produccion de formas farmaceuticas que contienen inhibidores de los canales task-1 y task-3 y su uso para la terapia de trastornos respiratorios.
MY198201A (en) A Combination Medicament Comprising Phenylephrine And Paracetamol
EA201992569A1 (ru) Способы и композиции для лечения апноэ во сне
NZ758564B2 (en) Methods and compositions for treating sleep apnea
MX2024007768A (es) Combinacion de un antagonista de adrenoreceptor a2 subtipo c (alfa-2c) con un inhibidor de recaptacion de norepinefrina para el tratamiento de apnea del sue?o.
JOP20210113A1 (ar) مناهضات لمستقبلات ألفا 2 الأدرينالية من النمط الثانوي سي (ألفا-2سي) لمعالجة انقطاع النفس أثناء النوم
EA201990341A1 (ru) Замещенные диазагетеробициклические соединения и их применение
CN302135101S (zh) 睡眠时的呼吸确保用管